MSMiyako Suzuki-Narita

Miyako Suzuki-Narita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miyako Suzuki-Narita has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of pain-related mechanisms and bone destruction in mild and severe monoiodoacetate-induced hip arthropathy in rats

    by Yasuhiro Furihata, Yuya Kawarai, Ikuko Tajiri, Kazuhide Inage, Miyako Suzuki-Narita, Rui Hirasawa, Shigeo Hagiwara, Junichi Nakamura, Jun-Ichiro Ikeda, Seiji Ohtori

    Background: This study aimed to characterize pain-related mechanisms and the bone-destructive environment in mild and severe monoiodoacetate (MIA)-induced hip arthropathy in rats, with particular focus on features relevant to rapidly destructive coxarthrosis. Methods: Rats were divided into sham, low-dose MIA, and high-dose MIA groups ( n = 12 per group) and received intra-articular injections of saline, low-dose MIA, or high-dose MIA, respectively. Pain-related behaviors were assessed using von Frey and weight-bearing tests. Radiological and histological changes were evaluated using microcomputed tomography and the Osteoarthritis Research Society International scoring system. The proportion of calcitonin gene-related peptide (CGRP)-immunoreactive dorsal root ganglion (DRG) neurons and the number of ionized calcium-binding adaptor molecule 1 (Iba1)-immunoreactive microglia in the spinal dorsal horn were quantified immunohistochemically. Synovial mRNA expression of tumor necrosis factor-α ( Tnf-α ) and receptor activator of nuclear factor-kappa B ligand ( Rankl ), as well as osteoclast-like multinucleated cells in the femoral head, were also quantified. Results: The high-dose MIA group showed significantly greater mechanical hypersensitivity and reduced weight-bearing capacity than the low-dose MIA and sham groups. This group also demonstrated more severe joint destruction, higher OARSI scores, a higher proportion of CGRP-immunoreactive DRG neurons, and an increased number of Iba1-immunoreactive microglia in the spinal dorsal horn. Synovial Tnf-α and Rankl mRNA expression levels were significantly increased in the high-dose MIA group compared with those in the sham and low-dose MIA groups. These changes were accompanied by an increased number of osteoclast-like multinucleated cells and bone resorption cavities compatible with Howship’s lacunae in the femoral head. Conclusions: High-dose MIA-induced hip arthropathy was characterized by more severe pain-related behavior, a higher proportion of CGRP-immunoreactive DRG neurons, an increased number of Iba1-immunoreactive microglia in the spinal dorsal horn, and a more pronounced osteoclast-associated bone-destructive environment than low-dose MIA-induced hip arthropathy. These findings suggest that the high-dose MIA model exhibits several experimental features relevant to rapidly destructive hip disease.

  • Open Access

    Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab–Denosumab Therapy for Severe Osteoporosis

    by Akira Kuwabara, Kazuhide Inage, Masaomi Yamashita, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masahiro Inoue, Miyako Suzuki-Narita, Takahisa Hishiya, Kohei Okuyama, et al.

    Kuwabara A, et al. Yonsei Med J. 2026 Sep;67(9):680-685. https://doi.org/10.3349/ymj.2025.0262

  • Impact of Intra‐Articular Diclofenac Etalhyaluronate on Pain and Osteoarthritic Changes in Advanced and End‐Stage Hip Osteoarthritis

    by Hiroakira Terakawa, Yuya Kawarai, Ikuko Tajiri, Kazuhide Inage, Miyako Suzuki‐Narita, Jun Takeuchi, Rui Hirasawa, Shigeo Hagiwara, Junichi Nakamura, Seiji Ohtori

    Diclofenac etalhyaluronate combines the sustained‐release properties of diclofenac with the therapeutic benefits of hyaluronic acid, providing extended analgesic effects for osteoarthritis management. This study investigated the effects of diclofenac etalhyaluronate and subsequent osteoarthritic changes in rat models of advanced and end‐stage osteoarthritis. Monosodium iodoacetate (0.5 or 2.0 mg) was injected directly into the right hip joint of rats (n = 8 rats/group) using a posterior approach to induce osteoarthritis. Four weeks after monosodium iodoacetate administration, diclofenac etalhyaluronate (0.25 mg/25 µL) or 25 µL saline was administered in the same way. Pain behavior, number of microglia in the dorsal horn of the spinal cord, radiological features on microcomputed tomography, and histology of the hip joint were evaluated. Administration of diclofenac etalhyaluronate increased the pain threshold and reduced the number of microglia in the dorsal horn of the spinal cord in both models. However, radiological and histological examinations did not detect significant arthritic changes in either group that received diclofenac etalhyaluronate. Intra‐articular administration, therefore, contributes to pain relief and improvement of central sensitization in advanced and end‐stage osteoarthritis of the hip without subsequent progression of osteoarthritis. These findings highlight the potential of intra‐articular administration of diclofenac etalhyaluronate as a conservative treatment option for advanced and end‐stage hip osteoarthritis, particularly for patients who may be unsuitable for surgery or have limited response to oral nonsteroidal anti‐inflammatory drugs.


  • Open Access

    Predictive Factors for Increased Bone Density Following Romosozumab Administration Based on Pre-Administration Blood Test Results

    by Akira Kuwabara, Kazuhide Inage, Masaomi Yamashita, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masahiro Inoue, Miyako Suzuki-Narita, Takahisa Hishiya, Takahito Arai, et al.

    Kuwabara A, et al. Yonsei Med J. 2024 Dec;66:e11. https://doi.org/10.3349/ymj.2023.0535


  • Comparison of effects of intra‐articular diclofenac etalhyaluronate and hyaluronic acid in a monoiodoacetate rat osteoarthritis model

    by Soichiro Tokeshi, Miyako Suzuki‐Narita, Ikuko Tajiri, Kazuhide Inage, Jun Takeuchi, Takahito Arai, Yuya Kawarai, Hiroakira Terakawa, Seiji Ohtori, Sumihisa Orita

    Diclofenac etalhyaluronate (DF‐HA) sustained diclofenac release with the effects of hyaluronic acid (HA), offering long‐term analgesia in osteoarthritis. In this study, the effects of DF‐HA on pain improvement and osteoarthritis were evaluated in a rat knee monoiodoacetate‐induced osteoarthritis model compared to HA. Eight rats per group had been injected with monoiodoacetate (2.0 mg) or saline in the right knee for 4 weeks and were injected with either DF‐HA (1.25 mg/kg; 0.5 mg), HA (0.5 mg), vehicle which was a substrate without DF‐HA (50 μL), or saline and followed for 4 weeks. Mechanical plantar skin sensitivity was assessed weekly using the von Frey assay. Osteoarthritis changes were monitored with Larsen scores via CT imaging at every 2 weeks. The articular cartilage was analyzed using OARSI scores through H&E, Safranin‐O staining at 8 weeks. The percentage of Iba‐1 positive microglia in the spinal dorsal horn and of FG + CGRP‐labeled cells among FG‐positive cells in the dorsal root ganglion were evaluated by immunohistochemical staining. TNF‐α and IL‐6 mRNA expression levels in the knee synovium were evaluated by PCR. The DF‐HA showed significantly improved pain hypersensitivity compared with the HA at 6–8 weeks. The percentage of Iba‐1‐positive microglia was significantly lower than that in the vehicle and the percentage of FG + CGRP/FG was significantly lower than that in the HA. OARSI scores did not differ among treatment groups, Larsen scores indicated lower in the DF‐HA than in the vehicle. DF‐HA was as effective as HA in joint protection and significantly improved inflammatory pain compared to HA.


  • Exercise improves load bearing bone structural properties in female secreted protein acidic and rich in cysteine (SPARC) null mice but not in males

    by Giselle Kaneda, Dave Huang, Nathalie Pham, Alfonso R. Gonzalez, Wafa Tawackoli, Seunghwan Lee, Miyako Suzuki, Trevor J. Nelson, Juliane D. Glaeser, Magali Millecamps, et al.

    Secreted protein acidic and rich in cysteine (SPARC) is the most abundant glycoprotein in bone and is thought to play a critical role in bone remodeling and homeostasis. However, the effect of SPARC in relation to gender and exercise on bone quality is not well understood. The purpose of this study was to quantify differences in the structural and biomechanical properties between calvarial and femoral bone from male and female wild‐type (WT) and SPARC null (SPARC(−/−)) mice as well as the ability of exercise to rescue bone health. Male and female WT and transgenic SPARC(−/−) mice were given either a fixed or rotating running wheel for exercise. Bone structural, biomechanical, and morphological parameters were quantified using micro computed tomography, push out testing for the calvaria, three‐point flexural testing for the femurs, histological and immunofluorescent staining. Similar reductions in structural and biomechanical strength were observed in both male and female SPARC(−/−) calvaria, most of which were not significantly affected by exercise. In femurs, SPARC(−/−) had a significant effect on structural parameters in both sexes, but was more pronounced in females with some properties being rescued with running. Interestingly, the effect of SPARC(−/−) on bone mineral density was only detected in female SPARC(−/−) mice, not males, and was subsequently rescued with exercise. This study emphasizes the differences between sexes in WT and SPARC(−/−) mice in regard to structural parameters and biomechanical properties. Research into gender differences can help inform and personalize treatment options to more accurately meet patient needs.


  • Bone union‐promoting effect of romosozumab in an ovariectomized rat posterolateral lumbar fusion model

    by Kohei Okuyama, Kazuhide Inage, Geundong Kim, Tomohito Mukaihata, Ikuko Tajiri, Yasuhiro Shiga, Masahiro Inoue, Yawara Eguchi, Miyako Suzuki‐Narita, Takuma Otagiri, et al.

    Spinal fixation surgery has been increasingly performed in patients with osteoporosis. Romosozumab, a drug that was introduced in Japan recently, is known to possibly promote bone healing. However, few studies have reported the therapeutic effects of romosozumab in clinical practice in Japan. Therefore, here, we investigated the effects of romosozumab dosage on bone fusion promotion using an ovariectomized rat spinal fusion model. Eight‐week‐old female Sprague‐Dawley rats were matched by body weight and divided into three groups: 1.0 romosozumab (R) group (Evenity®, 25 mg/kg), 1/10R group (Evenity®, 2.5 mg/kg), and control (C) group (saline). Subcutaneous injections were administered twice a week for 8 weeks postoperatively. Computed tomography scans were performed every 2 weeks from the time of surgery till 8 weeks postoperatively. The mean fusion rates in terms of volume were significantly higher in the R groups [1/10R, 1.0R] than in the C group from 4 weeks postoperatively. The rate of increase was significantly higher in the 1.0R group from 4 weeks postoperatively and in the 1/10R group from 6 weeks postoperatively, than in the C group. The proportion of trabecular bone area was approximately 1.5 times higher in the R groups than in the C group. No significant differences were observed between the R groups. Our results suggest that romosozumab stimulates bone growth at the graft site, and similar effects were achieved at 1/10 of the standard dosage.


  • Bone union‐promoting effect of romosozumab in a rat posterolateral lumbar fusion model

    by Geundong Kim, Kazuhide Inage, Yasuhiro Shiga, Tomohito Mukaihata, Ikuko Tajiri, Yawara Eguchi, Miyako Suzuki‐Narita, Hiromitsu Takaoka, Takashi Hozumi, Norichika Mizuki, et al.

    This study investigated the effect of romosozumab on bone union in a rat posterolateral lumbar fixation model. Posterolateral lumbar fixation was performed on 8‐week‐old male Sprague Dawley rats (n = 20). For bone grafting, autogenous bone (40 mg) was harvested from the spinous processes of the 10th thoracic vertebra until the 2nd lumbar vertebra and implanted between the intervertebral joints and transverse processes of the 4th and 5th lumbar vertebrae on both sides. Rats were matched by body weight and equally divided into two groups: R group (Evenity®, 25 mg/kg) and control (C) group (saline). Subcutaneous injections were administered twice a week until 8 weeks after surgery. Computed tomography was performed at surgery and week 8 after surgery. The area and percentage of bone trabeculae in the total area of bone fusion were calculated. Statistical analysis was performed using an unpaired t test (p < 0.05). We found that the R group rats had significantly higher mean bone union rate and volume than did the C group rats at all time courses starting week 4 after surgery. The R group had significantly higher increase rates than did the C group at weeks 4 and 6 after surgery. The percentage of bone trabeculae area in the R group was approximately 1.7 times larger than that in the C group. Thus, we demonstrated that romosozumab administration has stimulatory effects on bony outgrowth at bone graft sites. We attribute this to the modeling effect of romosozumab.


  • Analgesic effects and arthritic changes following tramadol administration in a rat hip osteoarthritis model

    by Keijiro Kanno, Miyako Suzuki‐Narita, Yuya Kawarai, Shigeo Hagiwara, Satoshi Yoh, Junichi Nakamura, Sumihisa Orita, Kazuhide Inage, Takane Suzuki, Seiji Ohtori

    We investigated the analgesic effects of tramadol and the arthritic changes following tramadol administration in the rat hip osteoarthritis (OA) model using mono‐iodoacetate (MIA). The right hip joints of male Sprague–Dawley rats (n = 5 rats/group) in the Sham group were injected with 25 μl of sterile saline and 1% of fluorogold (FG) retrograde neurotracer. In the MIA + Vehicle and MIA + Tramadol groups, FG and 25 μl of sterile saline with 0.5 mg of MIA were injected into the right hip joint. The MIA + Vehicle and MIA + Tramadol groups were administered daily for 4 weeks, either sterile saline (10 mg/kg, intraperitoneal [i.p.]) or tramadol (10 mg/kg, i.p.). We assessed hyperalgesia every week after MIA administration. Histopathological changes and immunoreactive neurons for calcitonin gene‐related peptide (CGRP) in dorsal root ganglia (DRG) were evaluated after 4 weeks of treatment. MIA injection into the hip joint led to mechanical hyperalgesia (p < 0.01), which was significantly reduced by tramadol administration (p < 0.01). Furthermore, daily i.p injection of tramadol significantly suppressed CGRP expression in DRG (p < 0.0001). MIA + Vehicle and MIA + Tramadol groups showed significant cartilage reduction and degeneration compared to the Sham group (p < 0.0001). Interestingly, OA changes significantly progressed in the MIA + Tramadol group compared to the MIA + Vehicle group (p < 0.0001).


  • Open Access

    Exercise attenuates low back pain and alters epigenetic regulation in intervertebral discs in a mouse model

    by Yuya Kawarai, Seon Ho Jang, Seunghwan Lee, Magali Millecamps, HyungMo Kang, Stephanie Gregoire, Miyako Suzuki-Narita, Seiji Ohtori, Laura S. Stone